Immune checkpoint inhibitors have shown promise in bladder cancer, especially among patients with high expression of PD-L1/PD-1, leading to the approval of PD-L1 and PD-1 targeted therapies in second and cisplatin-ineligible first-line therapy settings [7,9,10,11]. The gene discussed is CD274; the disease is urinary bladder cancer.